September 3, 2023
I have had IFS sessions with one client on multiple occasions with a self-administered psycholytic dose of psilomethoxin (Pm). In addition, I have shared Pm with five people Z, M, W, K1, and K2. What surprised me most from this exploration is that Pm seems to have a built-in exit valve. Or from the opposite point of view, the user only experiences the effects of Pm when focused inside. If you focus outside then you can completely miss the effects.
May 3, 2023
Abstract: The use of psychedelics in therapy may benefit both the client and the facilitator, and there is a debate about whether facilitators should have personal experience with the substance. While some traditions expect the facilitator to partake in the same dose as the participants, modern medicine expects the facilitator to remain sober. Facilitator sobriety is important to attend to the risks associated with psychedelic use, while communal use of the substance may increase empathy and compassion.
February 16, 2023
At the end of 2022, a new psychedelic became available. Psilomethoxin (Pm) offers soothing comfort similar to MDMA, but without MDMA’s stimulant-like effects.
In 1965, Marc Julia’s group at the Pasteur Institute synthesized psilomethoxin (Pm) from ortho-vanillin extracted from the Mexican vanilla orchid. The molecule was never bioassayed nor preserved as a reference sample, and that is how things stood for decades. The synthesis of Pm is an intricate and time-consuming process, with some chemists claiming that it would take a month.